Company intelligence / Profile preview

Jerini AG

Ownership: Private
Employees: ~139
Development stage: Commercial

Overview

Jerini's lead compound Firazyr (icatibant) was approved for hereditary angioedema in all European Union member states in July 2008 and later received FDA approval on August 25, 2011. Their AMD compound (JSM 6427) showed significant efficacy in preclinical models.

Therapeutic areas: OphthalmologyOncologyImmunologyHematology
Modalities: Peptide-based drugsPeptidomimeticsSmall molecules
Industry: Biotech

Drug pipeline

2 assets

icatibant

Commercial

Indications: Hereditary angioedema

1 more asset in the full pipeline.

Request access →

Partnerships

Baxter International Inc.Kos Pharmaceuticals Inc.Alcon Research Ltd.

Beyond the preview

Go deeper on Jerini AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jerini AG.

Explore the full profile